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Apolipoprotein E phenotypes in hemodialysis patients. Patients on maintenance hemodialysis (HD) are at
Background. Apolipoprotein (apo) E polymorphism con- increased risk for atherosclerotic vascular disease, and
sists of three major isoproteins (E2, E3, and E4). Because of cardiovascular disease is the major cause of mortality intheir difference in a lipid-modulating effect, the polymorphism
this setting [4]. Uremic dyslipidemia has been proposedhas been reported to affect the morbidity of atherosclerosis in
as a primary cause for this increased prevalence of ath-general population. Therefore, in hemodialysis (HD) patients,
the apo E polymorphism may also modulate serum levels of erosclerotic complications [5, 6].
cholesterol and susceptibility to atherosclerotic vascular dis- However, little has been known about the influence
ease. of apo E polymorphism on uremic dyslipidemia in HDMethods. We determined apo E phenotypes in 493 HD pa-
patients. Moreover, whether apo E polymorphism hastients and 422 controls. We also investigated vascular risk pro-
an influence on the prevalence of atherosclerotic compli-file and measured postprandial serum levels of lipids and apos
in the dialysis patients. cations in dialysis patients remains to be clarified.
Results. We found a similar phenotype distribution and al-
lele frequency between HD patients and healthy controls. Se-
rum levels of total cholesterol, triglyceride, and apo A I, A II, METHODS
and C III did not differ significantly among patients with
We studied the prevalence of vascular disease and thephenotypes apo E2/3, E3/3, and E3/4. Patients with apo E3/4
had significantly lower levels of high-density lipoprotein choles- vascular risk profile, including the apo E phenotype, in
terol, significantly higher levels of low-density lipoprotein cho- a total of 512 randomly selected HD patients recruited
lesterol (LDL-C), and a higher atherogenic index than those from five dialysis centers in the Niigata and Fukui prefec-with apo E2/3 (LDL-C, 100 6 30 vs. 82 6 35 mg/dl, P , 0.01;
tures between 1995 and 1996. Patients with apo E pheno-the index, 3.3 6 1.7 vs. 2.3 6 1.3, P , 0.01). Patients with apo
types other than apo E2/3, apo E3/3, and apo E3/4 (N 5E3/4 showed a tendency toward higher levels of apo B than
patients with apo E2/3 or apo E3/3. Multiple logistic regression 19) were excluded from this study to evaluate exactly
analysis revealed that age and diabetes mellitus, but not apo E the gene effect of three major alleles (E2, E3, and E4).
phenotypes, were independent risk factors for vascular disease.
The subjects of the study therefore consisted of 493 pa-Conclusions. Apo E polymorphism modulates cholesterol
tients. All patients were receiving four-hour sessions ofmetabolism in dialysis patients but appears to have little associ-
ation with the prevalence of atherosclerotic complications in HD three times per week, generally using high-flux mem-
the patients. branes and standard heparin doses for anticoagulation.
Informed consent for participation in study was obtained
from each subject. Smoking habits were defined on the
Hypercholesterolemia promotes atherosclerosis and basis of current cigarette smoking or previous smoking
has been suggested as a risk factor for chronic progressive history. Hypertension was defined as a systolic blood
kidney diseases [1]. Polymorphism of the apolipoprotein pressure of more than 140 mm Hg or a diastolic blood
(apo) E gene, which results in three main alleles, E2, pressure of more than 90 mm Hg or a history of use of
E3, and E4, modulates the lipid metabolism [2]. The apo antihypertensive drugs.
E2 isoprotein has a lipid-lowering effect, whereas apo E4
has a lipid-increasing effect because of their difference in Biochemical assays
affinity for lipoprotein receptors [3]. Thus, the apo E4
Venous blood samples of the subjects were collectedallele has been reported to be associated with a high
two to three hours after meals. Serum levels of totalprevalence of atherosclerosis in general population [2].
cholesterol (TC) and triglyceride (TG) were measured by
a standard enzymatic method and apos by immunoturbidi-
Key words: atherogenic index, atherosclerosis, hemodialysis, LDL- metry. High-density lipoprotein cholesterol (HDL-C) wascholesterol.
measured in the supernatant after precipitation of other
The first two authors contributed equally to this work. lipoprotein fractions with phosphotungstic acid. The se-
rum level of low-density lipoprotein cholesterol (LDL-C) 1999 by the International Society of Nephrology
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Table 1. Clinical and laboratory characteristics in hemodialysiswas calculated using the formula of Friedwald: TC 2
patients and healthy controls
(HDL-C) 2 (TG/5). Atherogenic index was calculated
Hemodialysis Healthyfrom the formula: (TC 2 HDL-C)/HDL-C. Blood sam-
patients controlsples for phenotyping of apo E were obtained from 434 N 5 493 N 5 422
healthy subjects without renal disease or apparent vascu-
Age year 58.7612.7a 48.3616.4
lar diseases. Only subjects with the apo E2/3, apo E3/3, Sex male/female 287/206b 277/145
Age at initiation of dialysis year 50.1616.0 —or apo E3/4 phenotype (N 5 422) served as controls.
Hemodialysis duration year 8.667.5 —
Hypertension % 73.8 —Determination of apo E phenotypes
Diabetes mellitus % 17.0 —
Smoking % 51.7 —Phenotyping of apo E was performed using a commer-
Total cholesterol mg/dl 161635a 196634 (N 5 261)cial kit (Phenotyping Apo E IEF System; Jokho Co.,
HDL-cholesterol mg/dl 46.9617.0a 55.7612.9 (N 5 191)
Tokyo, Japan) [7]. Triglyceride mg/dl 99653c 112674 (N 5 261)
ApoE phenotype
E2/3 53 (10.8%) 41 (9.7%)Assessment of vascular disease
E3/3 350 (71.0%) 316 (74.9%)
Coronary artery disease. Patients having a history of E3/4 90 (18.3%) 65 (15.4%)
ApoE isoproteinmyocardial infarction or a positive result in an exercise
E2 0.05 0.05test were diagnosed as having coronary artery disease.
E3 0.86 0.87
Peripheral vascular disease. Peripheral vascular disease E4 0.09 0.08
was diagnosed by diminished pulses on clinical examina- a P , 0.01 hemodialyis patients vs. healthy controls by Mann-Whitney U test
b P , 0.05 hemodialyis patients vs. healthy controls by chi-square analysistion combined with a comparison of ankle and arm sys-
c P , 0.05 hemodialyis patients vs. healthy controls by Mann-Whitney U testtolic blood pressures and/or peripheral angiography. An
ankle/arm index of less than 0.95 was taken as an indica-
tion of the presence of peripheral vascular disease.
Cerebral vascular disease. Cerebral vascular disease significantly among patient groups with the different
was suspected on clinical grounds, that is, a history of phenotypes (Table 2). Patients with apo E3/4 had sig-
rapid development of signs of focal disturbances of cere- nificantly lowers levels of HDL-C and significantly higher
bral function such as hemiparesis or cerebellular ataxia. levels of LDL-C and a higher atherogenic index than
The diagnoses were confirmed by computed tomography those with apo E2/3 (Table 2). Levels of apo E were
or magnetic resonance imaging. significantly lower in patients with apo E3/4 than in pa-
A patient was considered as having a vascular disease tients with apo E2/3 or apo E3/3. Patients with apo E3/4
when at least one of these three defined vascular diseases showed a tendency toward higher levels of apo B than
was present. those with apo E2/3 or apo E3/3 (Table 2).
Atherosclerotic complications were identified in 95
Statistical analysis HD patients, who included 12 patients with apo E2/3,
Continuous variables were expressed as means 6 sd. 67 patients with apo E3/3, and 16 patients with apo E3/4.
Differences in continuous variables among groups were There were no significant differences in the prevalence
examined by a nonparametric test (Mann–Whitney of vascular disease among patient groups with apo E2/3,
U-test) and analysis of variance. Differences in noncon- E3/3, and E3/4 (22.6 vs. 19.7% vs. 18.8%, P 5 NS). To
tinuous variables among groups were determined by determine the independent risk factors for atheroscle-
chi-squared analysis. To determine the independent in- rotic complications, a multiple logistic regression model
fluence of clinical variables on the prevalence of athero- was constructed which included age (year), HD duration
sclerotic complications in the patients, multiple logistic (year), sex (male 5 1, female 5 0), smoking (absent 5 0,
regression analysis was used. All statistic analyses were present 5 1), hypertension (absent 5 0, present 5 1),
conducted using the SPSS software program. A P value diabetes mellitus (absent 5 0, present 5 1), TC, HDL-C,
of less than 0.05 was considered to denote statistical and presence of apo E2 isoprotein (E3/3 5 0, E3/4 5 0,
significance. E2/3 5 1). This analysis revealed that age [odds ratio
(OR), 1.077; P , 0.001) and diabetes mellitus (OR, 6.17;
P , 0.001), but not apo E phenotype, were independentRESULTS
risk factors for vascular disease.
The clinical and laboratory profiles of the HD patients
and healthy controls are shown in Table 1. Apo E pheno-
DISCUSSIONtype distribution and allele frequency were not signifi-
cantly different between HD patients and healthy con- In this study, we showed that apo E polymorphism
trols (Table 1). The mean serum postprandial levels of modulates the serum postprandial levels of lipids in HD
patients and that patients with the apo E3/4 phenotypeTC, TG, and apo A I, A II, and C III did not differ
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Table 2. Comparison of clinical and laboratory characteristics closely associated with aortic atherosclerosis [6], and apo
among apoE phenotypes
E4 allele may have no influence on the serum IDL-C
E2/3 E3/3 E3/4 levels [10].
Variables N 5 53 N 5 350 N 5 90 In conclusion, the apo E polymorphism appears to
Age year 57.5611.9 59.0 613.1 58.5 611.5 modulate lipid metabolism in HD patients. A prospec-
Sex male/female 33/20 199/151 55/35
tive study will be required to clarify whether the apo EAge at initiation of dialysis year 48.3615.6 50.5 616.2 49.5 615.5
Hemodialysis duration year 9.268.0 8.4 67.4 9.1 67.5 polymorphism affects susceptibility to vascular disease
Hypertension % 81.0 75.0 65.0 in dialysis patients.
Diabetes mellitus % 13.2 17.7 16.7
Smoking % 51.0 50.9 55.6
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